Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.86
+1.3%
$21.04
$17.24
$28.56
$13.84B0.941.25 million shs1.05 million shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$212.55
-1.1%
$208.09
$170.00
$292.80
$14.21B0.9135 shs134 shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$134.75
+0.5%
$133.45
$118.05
$200.56
$17.42B0.961,063 shs384 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$36.12
+0.7%
$34.13
$24.05
$36.56
$20.17B0.53.71 million shs2.34 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+1.55%+5.58%-3.01%+19.82%-15.83%
Genmab A/S stock logo
GNMSF
Genmab A/S
+8.31%+4.88%-1.43%+20.11%-14.01%
Merck KGaA stock logo
MKGAF
Merck KGaA
+1.74%-0.46%-1.89%+10.09%-17.99%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
+1.01%-0.88%+7.43%+14.93%+39.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
4.1654 of 5 stars
3.35.00.00.03.40.03.1
Genmab A/S stock logo
GNMSF
Genmab A/S
0.8091 of 5 stars
0.03.00.00.02.20.01.3
Merck KGaA stock logo
MKGAF
Merck KGaA
1.2859 of 5 stars
0.01.00.00.02.00.03.1
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
4.8932 of 5 stars
3.61.03.33.73.61.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.67
Moderate Buy$37.8072.92% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
4.00
Strong BuyN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.25
Buy$48.3333.81% Upside

Current Analyst Ratings Breakdown

Latest GMAB, GNMSF, MKGAF, and RPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$51.00 ➝ $54.00
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
5/16/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$51.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.49$1.54 per share14.23$8.04 per share2.72
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.50$15.01 per share14.16$80.53 per share2.64
Merck KGaA stock logo
MKGAF
Merck KGaA
$22.72B0.77$40.59 per share3.32$212.00 per share0.64
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.26B8.97$4.22 per share8.55$17.56 per share2.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.4212.286.5635.11%18.08%14.52%8/14/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6312.06N/A35.11%19.23%15.44%8/7/2025 (Estimated)
Merck KGaA stock logo
MKGAF
Merck KGaA
$3.06B$6.8120.5712.77N/A12.60%10.17%5.74%8/7/2025 (Estimated)
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$858.98M$1.8519.527.431.8448.23%24.71%13.87%8/6/2025 (Estimated)

Latest GMAB, GNMSF, MKGAF, and RPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
5/8/2025Q1 2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.99$1.06+$0.07$0.41$724.69 million$839.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.882.44%N/A47.57%5 Years

Latest GMAB, GNMSF, MKGAF, and RPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/21/2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.222.7%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.34
5.32
Merck KGaA stock logo
MKGAF
Merck KGaA
0.27
1.31
0.84
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.68
1.56
1.56

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
0.10%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Merck KGaA stock logo
MKGAF
Merck KGaA
N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.66 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.07 million65.06 millionNot Optionable
Merck KGaA stock logo
MKGAF
Merck KGaA
62,908129.24 millionN/ANot Optionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
80562.24 million455.98 millionOptionable

Recent News About These Companies

RPRX Royalty Pharma plc - Seeking Alpha
Royalty Pharma plc (RPRX) Balance Sheet - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.86 +0.28 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$22.06 +0.20 (+0.91%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$212.55 -2.45 (-1.14%)
As of 09:33 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKGAF

$134.75 +0.66 (+0.49%)
As of 03:51 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$36.12 +0.25 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$36.20 +0.08 (+0.21%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.